These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20184575)

  • 1. Insulin resistance increases the risk of urinary stone formation in a rat model of metabolic syndrome.
    Iba A; Kohjimoto Y; Mori T; Kuramoto T; Nishizawa S; Fujii R; Nanpo Y; Matsumura N; Shintani Y; Inagaki T; Hara I
    BJU Int; 2010 Nov; 106(10):1550-4. PubMed ID: 20184575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
    Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
    Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver.
    Matsuura B; Kanno S; Minami H; Tsubouchi E; Iwai M; Matsui H; Horiike N; Onji M
    J Gastroenterol; 2004; 39(4):339-45. PubMed ID: 15168245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
    Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatments for insulin resistance: trim the fat and douse the fire.
    Evans JL; Youngren JF; Goldfine ID
    Trends Endocrinol Metab; 2004 Nov; 15(9):425-31. PubMed ID: 15519889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation.
    Dandona P; Aljada A; Chaudhuri A; Mohanty P; Garg R
    Circulation; 2005 Mar; 111(11):1448-54. PubMed ID: 15781756
    [No Abstract]   [Full Text] [Related]  

  • 8. The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy.
    Wyne KL
    Diabetes Obes Metab; 2006 Jul; 8(4):365-80. PubMed ID: 16776743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance, diabetes and cardiovascular risk: approaches to treatment.
    Rosenberg DE; Jabbour SA; Goldstein BJ
    Diabetes Obes Metab; 2005 Nov; 7(6):642-53. PubMed ID: 16219008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.
    Meigs JB; Rutter MK; Sullivan LM; Fox CS; D'Agostino RB; Wilson PW
    Diabetes Care; 2007 May; 30(5):1219-25. PubMed ID: 17259468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic syndrome: are we at risk?
    Paudel B
    Nepal Med Coll J; 2007 Sep; 9(3):204-11. PubMed ID: 18092442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones.
    Yki-Järvinen H
    N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
    [No Abstract]   [Full Text] [Related]  

  • 13. Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X.
    Seda O; Kazdová L; Krenová D; Kren V
    Folia Biol (Praha); 2002; 48(6):237-41. PubMed ID: 12512799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Against insulin resistance. Insulin sensitizers].
    Verspohl EJ; Weiland F
    Pharm Unserer Zeit; 2002; 31(3):280-92. PubMed ID: 12071125
    [No Abstract]   [Full Text] [Related]  

  • 15. Impaired insulin-regulated membrane aminopeptidase translocation to the plasma membrane in adipocytes of Otsuka Long Evans Tokushima Fatty rats.
    Takeuchi M; Itakura A; Okada M; Mizutani S; Kikkawa F
    Nagoya J Med Sci; 2006 Jun; 68(3-4):155-63. PubMed ID: 16967782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of adipose tissue redistribution with rosiglitazone treatment in various adipose depots.
    Kang JG; Park CY; Ihm SH; Yoo HJ; Park H; Rhee EJ; Won JC; Lee WY; Oh KW; Park SW; Kim SW
    Metabolism; 2010 Jan; 59(1):46-53. PubMed ID: 19716145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes.
    Phillips JW; Barringhaus KG; Sanders JM; Yang Z; Chen M; Hesselbacher S; Czarnik AC; Ley K; Nadler J; Sarembock IJ
    Circulation; 2003 Oct; 108(16):1994-9. PubMed ID: 14517165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keishibukuryogan ameliorates glucose intolerance and hyperlipidemia in Otsuka Long-Evans Tokushima Fatty (OLETF) rats.
    Nakagawa T; Goto H; Hussein G; Hikiami H; Shibahara N; Shimada Y
    Diabetes Res Clin Pract; 2008 Apr; 80(1):40-7. PubMed ID: 18242756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat.
    Taniguchi Y; Ooie T; Takahashi N; Shinohara T; Nakagawa M; Yonemochi H; Hara M; Yoshimatsu H; Saikawa T
    Diabetes; 2006 Aug; 55(8):2371-8. PubMed ID: 16873703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.